Balyasny Asset Management LLC Avadel Pharmaceuticals PLC Transaction History
Balyasny Asset Management LLC
- $54.8 Billion
- Q1 2024
A detailed history of Balyasny Asset Management LLC transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, Balyasny Asset Management LLC holds 309,712 shares of AVDL stock, worth $4.35 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
309,712
Previous 781,515
60.37%
Holding current value
$4.35 Million
Previous $11 Million
52.59%
% of portfolio
0.01%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding AVDL
# of Institutions
133Shares Held
68.4MCall Options Held
1.01MPut Options Held
2.03M-
Janus Henderson Group PLC London, X012.9MShares$182 Million0.12% of portfolio
-
Rtw Investments, LP New York, NY8.8MShares$124 Million2.38% of portfolio
-
Polar Capital Holdings PLC London, X06.75MShares$95 Million0.71% of portfolio
-
Gendell Jeffrey L Greenwich, CT5.71MShares$80.3 Million3.76% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.97MShares$55.8 Million8.97% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $852M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...